Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma

Roelants Caroline; Giacosa Sofia; Pillet Catherine; Bussat Rémi; Champelovier Pierre; Bastien Olivier; Guyon Laurent; Arnoux Valentin; Cochet Claude; Filhol Odile

doi:10.18632/oncotarget.26807

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma

PDF | How to cite

Oncotarget. 2019; 10:2236-2236. https://doi.org/10.18632/oncotarget.26807

Metrics: PDF 1241 views | ?

Roelants Caroline^1,2, Giacosa Sofia¹, Pillet Catherine³, Bussat Rémi¹, Champelovier Pierre⁴, Bastien Olivier⁵, Guyon Laurent¹, Arnoux Valentin⁴, Cochet Claude¹ and Filhol Odile¹

¹ Université Grenoble-Alpes, Inserm U1036, CEA, BIG-BCI, Grenoble, France
² Inovarion, Paris, France
³ Université Grenoble-Alpes, Inserm U1038, CEA, BIG-BGE, Grenoble, France
⁴ Centre Hospitalier Université Grenoble-Alpes, CS 10217, Grenoble, France
⁵ Université Grenoble-Alpes, CNRS-CEA-INRA, Laboratoire de Physiologie Cellulaire et Végétale, Grenoble, France

Published: March 15, 2019

This article has been corrected: The correct author information is given below:

Roelants Caroline^1,2, Giacosa Sofia¹, Pillet Catherine³, Bussat Rémi¹, Champelovier Pierre⁴, Bastien Olivier⁵, Guyon Laurent¹, Arnoux Valentin⁴, Cochet Claude¹ and Filhol Odile¹

Original article: Oncotarget. 2018; 9:30066-30078. DOI: https://doi.org/10.18632/oncotarget.25700.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26807

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma